警报剂IL-33在SARS-CoV-2感染中加剧肺炎和免疫功能障碍
Hui Wang1,2, Yashoda M Hosakote2,3, Paul J Boor1
1Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555, USA.
介素-33 (IL-33) 通过促进炎症和病毒复制,加剧了COVID-19的严重程度. 在小鼠中阻断IL-33减少了疾病症状和肺损伤,表明IL-33是治疗点.
科学领域:
- 免疫学 免疫学 免疫学
- 病毒学 病毒学
- 分子生物学分子生物学
背景情况:
- 失调的免疫反应加剧了COVID-19的结果.
- 导致COVID-19严重程度的机制尚未完全理解.
研究的目的:
- 调查介素-33 (IL-33) 在SARS-CoV-2感染中的作用.
- 确定IL-33是否有助于COVID-19的致病性.
主要方法:
- 在COVID-19患者和SARS-CoV-2感染小鼠中测量IL-33水平.
- 利用IL-33淘汰赛 (IL-33-/-) 小鼠来评估疾病的进展.
- 进行肺部RNA测序 (RNA-seq) 来分析炎症途径.
主要成果:
- 在COVID-19患者和感染的小鼠中,IL-33水平升高.
- 在小鼠中,IL-33缺乏导致体重减轻,病毒载量减少和肺病理.
- 在IL-33-/-小鼠中观察到降低的先天性免疫细胞透 (中性粒细胞,巨细胞,NK细胞,T细胞).
- IL-33信号放大了炎症途径,包括干扰素信号和巨细胞激活.
结论:
- 警报蛋白IL-33在SARS-CoV-2感染中起着致病作用.
- 阻断IL-33可能为COVID-19提供治疗策略.
- 研究结果提供了对严重COVID-19的宿主免疫反应的见解.
更多相关视频
10:30Author Spotlight: Developing a Microfluidic Lung-on-Chip Model for In-Depth Study of Human Immune Response and Infection Mechanisms
Published on: May 31, 2024
14:48Visualizing Lung Cellular Adaptations during Combined Ozone and LPS Induced Murine Acute Lung Injury
Published on: March 21, 2021
相关概念视频
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Pneumonia II: Pathophysiology
Pneumonia III: Complications and Assessment
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
